You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Production of 1.35 bn vaccine doses between August, December a long haul

Covishield production to cross 120 mn doses a month, Covaxin 58 mn doses a month

Topics
Coronavirus Vaccine | Coronavirus | Vaccination

Sohini Das  |  Mumbai 

Covaxin, Covishield, serum institute of india, bharat biotech, vaccine, vaccination, coronavirus, covid
According to Mandaviya’s statement in the Rajya Sabha, Covishield supplies would meet the target of 500 mn doses between August and December

Production of both Covishield and Covaxin – Covid-19 vaccines from (SII) and – is set to rise from next month. The target of 1.35 bn vaccine doses between August and December, however, looks like a long haul.

According to a response given in the Rajya Sabha, Health Minister Mansukh Mandaviya said recently that the monthly production capacity of Covishield is projected to increase from 110 mn doses to more than 120 mn doses a month, whereas the production capacity of Covaxin is projected to increase from 25 mn doses a month to around 58 mn doses a month.

Mandaviya added that apart from this, the Centre has also facilitated further capacity augmentation of Covaxin at central public sector enterprises including Haffkine Biopharmaceutical Corporation Ltd, Mumbai; Indian Immunologicals Limited (IIL), Hyderabad and Bharat Immunologicals Biologicals Limited (BIBCOL), Bulandshahr. “In addition, technology transfer of Covaxin production to Gujarat Covid Vaccine Consortium (GCVC), including Hester Biosciences and OmniBRx Biotechnologies Pvt Ltd, led by Gujarat Biotechnology Research Centre (GBRC), Department of Science and Technology, Govt. of Gujarat has also been facilitated,” he said.

At 58 mn doses a month, Covaxin production would roughly be around 232 mn doses between September and December. At 120 mn doses a month, Covishield production would roughly be around 480 mn doses a month.

According to an affidavit in the Supreme Court in June, the Union government had said that 1.35 bn doses would be needed to vaccinate the adult population between August and December. This was a downward revision of the earlier estimate of 2.1 bn doses that the Centre had indicated it expects between August and December.

In the affidavit, the Centre had noted that 1.86 to 1.88 billion doses are required to vaccinate the adult population of 930-940 million. Of this, 516 million doses will be made available by July 31, leaving a requirement of approximately 1.35 billion doses to complete the to the eligible population.

Of the 1.35 billion doses, 500 million will be of Covishield and 400 million of Covaxin. The government expects 100 million doses of Russian made Sputnik-V. Another 300 million will come from Biological E subunit vaccine and 50 mn from Zydus Cadila.

According to Mandaviya’s statement in the Rajya Sabha, Covishield supplies would meet the target of 500 mn doses between August and December. However, it looks like Covaxin would miss the target of 400 mn unless the partner sites of ramp up very rapidly.

Earlier this week, VK Paul, member (health) NITI Aayog said that the quantum jump in Covaxin supplies will come from Bharat Biotech’s Bengaluru facility. This has a large reactor and system established by them and the contribution of supplies have started coming, Paul had indicated.

Meanwhile, the Centre has also indicated that Indian Immunologicals Limited is likely to start supply of an additional 2 million doses of Covaxin from August-September. Also, Bharat Biotech’s Ankleshwar facility is likely to add 6 million doses over the next few months.

The details of projected availability of Covid -19 vaccines from August 2021 to December 2021 are as follows
Vaccine Quantity that may be available through all sources

May 13 estimates

Covishield

500 mn

750 mn

Covaxin

400 mn 550 mn
Biological E subunit vaccine 300 mn 300 mn

Sputnik V

100 mn 156 mn
Zydus Cadila DNA vaccine 50 mn 50 mn
SII-Novavax 0 200 mn

BB Nasal vaccine

0 100 mn
Gennova mRNA vaccine 0 60 mn
Total 1.35 bn 2.16 bn

Source: Affidavit filed by Union of India in Supreme Court. MoHFW said in Rajya Sabha in August - Covishield production – 120 mn doses per month; Covaxin production – 58 mn doses per month

Bharat Biotech’s Covaxin production faced a slowdown after its newly re-purposed manufacturing facility at Bengaluru (which has a large-scale fermentation plant) faced initial glitches during standardization of the first few batches in June and July. The company was supplying around 20 mn doses of Covaxin a month and that is projected to increase to 25 mn doses this month.

For the 1.35 bn doses roadmap, supplies of Russia’s Sputnik V, Biological E’s vaccine as well Zydus Cadila’s DNA-plasmid vaccine too are expected. Dr Reddy’s Laboratories, the distributor of Sputnik V in India has said it has so far received 3.15 mn doses of component 1 and 450,000 doses of component 2 of the Sputnik V vaccine in India. Supplies from Indian sites including SII are expected from September-October. Meanwhile, Zydus Cadila is awaiting the approval from India’s drug regulator, and Biological E is conducting clinical trials.

As of May 13, the Union health ministry had estimated 750 million doses of Covishield, 550 million of Covaxin, 156 million of Sputnik V, apart from 200 million of Novavax vaccine (made here by Serum Institute), 100 million of the nasal vaccine from Bharat Biotech, 60 mn of Gennova’s mRNA vaccine, and 50 mn of DNA-plasmid vaccine of Zydus.

Later in June, Novavax, Gennova mRNA and Bharat Biotech’s nasal vaccines were scrapped off the list.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, August 05 2021. 12:49 IST
RECOMMENDED FOR YOU